First Tracks Biotherapeutics Inc Stock Analysis & AI Score
First Tracks Biotherapeutics Inc (TRAX) has an ST Score of 58.8 (B-), driven by its Valuation (A-) and held back by its Growth (D+). Analysts rate it Buy with a $68.80 price target (+66.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AITRAX Stock Price History
TRAX Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
TRAX Latest Stock News
ST Score
First Tracks Biotherapeutics Inc (TRAX) has an ST Score of 58.8 (B-), driven by its Valuation (A-) and held back by its Growth (D+). Analysts rate it Buy with a $68.80 price target (+66.8% upside).
- Strongest
- ValuationA-
- Weakest
- GrowthD+
All factor grades
- ValuationA-
- Financial StrengthA-
- ForecastA-
- MomentumB
- ProfitabilityD+
- GrowthD+
Press Releases
Company Contact Details
TRAX stock: frequently asked questions
What is TRAX's ST Score?
First Tracks Biotherapeutics Inc (TRAX) has an ST Score of 58.8 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TRAX a buy, hold, or sell?
Analysts rate TRAX a Buy, with a price target of $68.80 (+66.8% vs the current price). Our ST Score grades it B- (58.8/100). The ST Score is a data-driven signal, not a recommendation.
What are TRAX's factor grades?
Valuation A-, Profitability D+, Financial Strength A-, Momentum B, Growth D+, Forecast A-.
What is TRAX's valuation grade?
First Tracks Biotherapeutics Inc (TRAX) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TRAX's growth grade?
First Tracks Biotherapeutics Inc (TRAX) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TRAX's profitability grade?
First Tracks Biotherapeutics Inc (TRAX) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TRAX's financial strength grade?
First Tracks Biotherapeutics Inc (TRAX) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TRAX?
The average analyst price target for First Tracks Biotherapeutics Inc (TRAX) is $68.80 from 9 analysts, which is +66.8% versus the recent price of $41.25.